FindTrial
Sign In

STUDY OF SILDENAFIL (A MEDICINE) TO REDUCE HIGH LUNG BLOOD PRESSURE IN PATIENTS ON REGULAR DIALYSIS

TO STUDY THE EFFECT OF SILDENAFIL IN MAINTAINANCE HAEMODIALYSIS PATIENTS WITH PULMONARY HYPERTENSION AT TERTIARY CARE CENTRE IN NORTH KARNATAKA - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/107104
Enrollment
20
Registered
2026-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: Nil: Nil

Sponsors

DR AKSHAY UMESH NAGARKAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PATIENT ON HAEMODIALYSIS TWICW WEEKLY MORE THAN 18 YEARS OF AGE

Exclusion criteria

Exclusion criteria: ON CURRENT PULMONARY HYPERTENSION TREATMENT HEART DISEASES LUNG DISEASES SYSTEMIC ILLNESS

Design outcomes

Primary

MeasureTime frame
TO EVALUATE THE EFFECT OF SILDENAFIL ON PULMONARY ARTERY PRESSURE IN HAEMODIALYSIS WITH PULMONARY HYPERTENSION AT BASELINE AND 3 MONTHS AFTER TREATMENT TO STUDY INCIDENCE OF PULMONARY HYPERTENSIONTimepoint: AT BASELINE AND AFTER 12 WEEKS—

Secondary

MeasureTime frame
TO EVALUATE THE EFFECT OF SILDENAFIL ON 6 MINUTE WALK TESTIN HAEMODIALYSIS PATIENTS WITH PULMONARY HYPERTENSIONTimepoint: AT BASELINE AND AFTER 3 MONTHS—

Countries

India

Contacts

Public ContactDr AKSHAY UMESH NAGARKAR

JNMC KLEs DR PRABHAKAR KORE HOSPITAL

rsarvi@yahoo.com9611556583

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026